In 2019, an independent mid-term review (MTR) was initiated to assess CEPI’s performance since its formation in 2017 through to December 2019. Following a competitive tender, MM Global Health Consulting was selected to undertake the independent review, which commenced in January 2020. During this review process, COVID-19 emerged as a pandemic threat, which required CEPI to pivot its organisational focus to support global R&D and manufacturing response efforts. In view of the pandemic’s impact on CEPI’s operations, the mid-term review process was completed in April 2020 and interim results were reported. This was then complemented with the COVID-19 Response Review (CRR), to evaluate CEPI’s response to the pandemic up to August, 2020.
